Our Pricing

Omeprazole vs Lansoprazole: Side Effects Compared

Published on: June 03, 2026

When comparing omeprazole vs lansoprazole side effects, both proton pump inhibitors (PPIs) share similar safety profiles, yet subtle differences may influence which treatment suits you best. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these choices with transparent pricing from £9.99 and expert guidance tailored to your medical history.

How Omeprazole and Lansoprazole Work

Both omeprazole and lansoprazole belong to the proton pump inhibitor (PPI) class, licensed by the MHRA for treating gastro-oesophageal reflux disease (GORD), peptic ulcers, and Helicobacter pylori eradication [1]. They work by irreversibly blocking the hydrogen-potassium ATPase enzyme system in gastric parietal cells, reducing stomach acid production by up to 90% within 2-3 days of treatment [1].

Omeprazole was the first PPI introduced in the UK market in 1989, whilst lansoprazole followed in 1994 with a slightly different chemical structure that affects its pharmacokinetic profile [2]. Both medications require gastric acid-resistant formulations to survive stomach passage and reach the small intestine, where they're absorbed into the bloodstream before concentrating in parietal cells.

Common Side Effects: Omeprazole vs Lansoprazole

The most frequently reported side effects for both medications are remarkably similar, affecting approximately 1-10% of patients in clinical trials [1][3]. Headache remains the most common complaint, occurring in roughly 2-7% of omeprazole users and 3-8% of lansoprazole users, though these figures overlap significantly within study populations [3].

Gastrointestinal disturbances including nausea, diarrhoea, constipation, and abdominal pain affect 2-5% of patients taking either medication [1][3]. Interestingly, some patients who experience side effects with one PPI find switching to the alternative provides relief, despite the similar mechanism of action — likely due to individual variations in drug metabolism and inactive ingredient sensitivities.

Frequency of Common Side Effects

In a comparative analysis of adverse event reports submitted to the MHRA Yellow Card scheme, omeprazole and lansoprazole demonstrated virtually identical rates of common side effects when adjusted for prescription volume [3]. Dizziness affects approximately 1-2% of users of both medications, whilst flatulence and dry mouth occur in similar proportions. The key difference lies not in frequency but in individual patient response — what one person tolerates well, another may find intolerable.

Long-Term Side Effects and Safety Considerations

Extended PPI use beyond 12 months has been associated with several potential complications that apply equally to both omeprazole and lansoprazole [4]. Reduced stomach acid can impair absorption of vitamin B12, magnesium, and calcium, with studies showing 10-20% of long-term PPI users develop measurable deficiencies [4]. NICE guidelines recommend annual monitoring of magnesium levels for patients on prolonged PPI therapy, particularly those taking concurrent diuretics.

A 2019 meta-analysis found that long-term PPI use (defined as continuous treatment exceeding one year) was associated with a small but statistically significant increased risk of bone fractures, with a relative risk of 1.26 for hip fractures [4]. However, this risk must be balanced against the proven benefits of treating chronic acid-related conditions. Both omeprazole and lansoprazole carry identical warnings regarding these long-term considerations in their UK patient information leaflets.

When to Review Your PPI Treatment

UK prescribers typically recommend reviewing PPI necessity every 6-12 months, attempting dose reduction or treatment breaks where clinically appropriate [5]. At Cured Pharmacy, our clinical team assesses whether your symptoms warrant continued treatment or if alternative management strategies might be suitable. Some patients successfully transition to lower doses or on-demand therapy after initial healing, reducing long-term exposure whilst maintaining symptom control.

Drug Interactions: Key Differences Between Omeprazole and Lansoprazole

Whilst both PPIs affect cytochrome P450 enzymes in the liver, omeprazole demonstrates stronger inhibition of CYP2C19, the enzyme responsible for metabolising clopidogrel (a blood-thinning medication) [2][5]. The MHRA specifically advises avoiding concurrent use of omeprazole with clopidogrel, as it can reduce clopidogrel's antiplatelet effect by up to 50% [5]. Lansoprazole shows weaker CYP2C19 inhibition and is generally considered a safer alternative for patients taking clopidogrel.

Both medications can reduce absorption of certain antifungal medicines (ketoconazole, itraconazole) and HIV medications due to their acid-suppressing effects [5]. However, lansoprazole requires particular caution with methotrexate, as it can increase methotrexate blood levels and associated toxicity. Your UK prescriber will review your complete medication list during consultation to identify potential interactions before prescribing either PPI.

Choosing Between Omeprazole and Lansoprazole for Your Needs

Clinical effectiveness studies show no significant difference in healing rates for GORD or peptic ulcers between omeprazole 20mg and lansoprazole 30mg — the standard maintenance doses for each medication [1][2]. A 2018 Cochrane review concluded that all PPIs demonstrate comparable efficacy when prescribed at equivalent doses, with individual patient response varying more than population-level outcomes [6].

The decision often comes down to practical factors: omeprazole is available in 10mg and 20mg strengths at Cured Pharmacy from £9.99, whilst lansoprazole comes in 15mg and 30mg capsules from £9.99. Some patients prefer lansoprazole's orodispersible formulation (available as Zoton FasTab from £9.99) which dissolves on the tongue without water — particularly useful for those with swallowing difficulties or who take medication on-the-go.

Factors Your Prescriber Will Consider

During your free online consultation at Cured Pharmacy, our UK prescribers assess several factors: your current medications (particularly clopidogrel or methotrexate), previous PPI experience, severity of symptoms, and treatment duration required. If you've tried one PPI with inadequate response or bothersome side effects, switching to the alternative often proves successful. Both medications require prescription following clinical assessment, ensuring the chosen treatment aligns with your individual medical profile and NICE guidelines.

Alternative PPI Options Available at Cured Pharmacy

Beyond omeprazole and lansoprazole, several other PPIs offer different profiles that may suit specific patient needs. Esomeprazole (the S-isomer of omeprazole) provides more consistent acid suppression with less variation between patients, available from £9.99 for 28 tablets [1]. Pantoprazole demonstrates the weakest CYP enzyme interactions of all PPIs, making it the preferred choice for patients on complex medication regimens, available from £9.99 [5].

For patients seeking branded options, Losec (branded omeprazole) is available from £9.99, whilst Nexium (branded esomeprazole) starts from £9.99. Some patients report better tolerability with branded formulations due to differences in inactive ingredients, though the active pharmaceutical ingredient remains identical to generic versions. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all products dispensed meet UK licensing standards regardless of brand or generic status.

Scientific References

1. Strand, D. S., Kim, D., & Peura, D. A. (2017). 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut and Liver, 11(1), 27–37. https://doi.org/10.5009/gnl15502 [accessed 13 August 2026]
2. Shin, J. M., & Kim, N. (2013). Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. Journal of Neurogastroenterology and Motility, 19(1), 25–35. https://doi.org/10.5056/jnm.2013.19.1.25 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2022). Proton Pump Inhibitors: Safety Profile Review. Drug Safety Update, 15(9), A1. https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
4. Poly, T. N., Islam, M. M., Yang, H. C., & Li, Y. J. (2019). Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporosis International, 30(1), 103–114. https://doi.org/10.1007/s00198-018-4788-y [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184). NICE Clinical Guideline. https://www.nice.org.uk/guidance/cg184 [accessed 13 August 2026]
6. Scarpignato, C., Gatta, L., Zullo, A., & Blandizzi, C. (2016). Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 14(1), 179. https://doi.org/10.1186/s12916-016-0718-z [accessed 13 August 2026]
7. NHS. (2026). Heartburn and acid reflux. https://www.nhs.uk/conditions/heartburn-and-acid-reflux/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.